Viravaxx submits Hepatitis B abstract to AASLD
Vienna, June 17, 2021. Viravaxx’ ongoing phase II clinical trial (NCT03625934) investigates if vaccination with VVX001 can induce a preS-specific antibody response in vaccine naïve adults and in patients chronically infected with HBV. In the trial, 4 cohorts are enrolled in a prospective double-blind, placebo-controlled clinical study. Cohort 1: vaccine naïve subjects; cohort 2: subjects | read more »
Vienna, June 17, 2021. Viravaxx’ ongoing phase II clinical trial (NCT03625934) investigates if vaccination with VVX001 can induce a preS-specific antibody response in vaccine naïve adults and in patients chronically infected with HBV. In the trial, 4 cohorts are enrolled in a prospective double-blind, placebo-controlled clinical study. Cohort 1: vaccine naïve subjects; cohort 2: subjects having failed to seroconvert upon vaccination with a licensed HBV vaccine; cohort 3: patients who are chronically infected with HBV but are classified as inactive carriers; cohort 4: patients with active chronic HBV infection who are HbEAg negative and chronically treated with nucleo(t)side analogues (NUCs). To date, cohort 1 (n=12) and cohort 3 (n=12) have been completed. The abstract will be published at the American Association for the study of Liver Diseases (AASLD) conference in San Diego, California.